Last reviewed · How we verify

Polichem S.A. — Portfolio Competitive Intelligence Brief

Polichem S.A. pipeline: 0 marketed, 0 filed, 7 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
P-3073 P-3073 phase 3 PI3K delta inhibitor PI3K delta Immunology
P-3058 10% P-3058 10% phase 3 SGLT2 inhibitor SGLT2 Diabetes
P-3058 P-3058 phase 3 SGLT2 inhibitor SGLT2 Diabetes
P-3074 P-3074 phase 3 SGLT2 inhibitor SGLT2 Diabetes
vehicle of P-3058 10% vehicle of P-3058 10% phase 3
P-3074 Vehicle P-3074 Vehicle phase 3
amorolfine 5% amorolfine 5% phase 3 Antifungal Lanosterol 14α-demethylase Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 2 shared drug classes
  2. Addpharma Inc. · 2 shared drug classes
  3. Astellas Pharma Inc · 2 shared drug classes
  4. AstraZeneca · 2 shared drug classes
  5. Novartis · 2 shared drug classes
  6. Shandong New Time Pharmaceutical Co., LTD · 2 shared drug classes
  7. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  8. AceLink Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Polichem S.A.:

Cite this brief

Drug Landscape (2026). Polichem S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/polichem-s-a. Accessed 2026-06-10.

Related